Literature DB >> 25103559

Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs.

Laurence Booth1, Jane L Roberts1, Nichola Cruickshanks1, Steven Grant2, Andrew Poklepovic2, Paul Dent3.   

Abstract

The present studies examined the toxic interaction between the non-coxib celecoxib derivative OSU-03012 and phosphodiesterase 5 (PDE5) inhibitors, and also determined the roles of endoplasmic reticulum stress response regulators in cell survival. PDE5 inhibitors interacted in a greater than additive fashion with OSU-03012 to kill parental glioma and stem-like glioma cells. Knockdown of the endoplasmic reticulum stress response proteins IRE1 or XBP1 enhanced the lethality of OSU-03012, and of [OSU-03012 + PDE5 inhibitor] treatment. Pan-caspase and caspase-9 inhibition did not alter OSU-03012 lethality but did abolish enhanced killing in the absence of IRE1 or XBP1. Expression of the mitochondrial protective protein BCL-XL or the caspase-8 inhibitor c-FLIP-s, or knockdown of death receptor CD95 or the death receptor caspase-8 linker protein FADD, suppressed killing by [OSU-03012 + PDE5 inhibitor] treatment. CD95 activation was blocked by the nitric oxide synthase inhibitor L-NAME. Knockdown of the autophagy regulatory proteins Beclin1 or ATG5 protected the cells from OSU-03012 and from [OSU-03012 + PDE5 inhibitor] toxicity. Knockdown of IRE1 enhanced OSU-03012/[OSU-03012 + PDE5 inhibitor]-induced JNK activation, and inhibition of JNK suppressed the elevated killing caused by IRE1 knockdown. Knockdown of CD95 blunted JNK activation. Collectively, our data demonstrate that PDE5 inhibitors recruit death receptor signaling to enhance OSU-03012 toxicity in glioblastoma multiforme (GBM) cells. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25103559      PMCID: PMC4185238          DOI: 10.1158/1535-7163.MCT-14-0172

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  57 in total

1.  OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.

Authors:  Adly Yacoub; Margaret A Park; David Hanna; Young Hong; Clint Mitchell; Aditi P Pandya; Hisashi Harada; Garth Powis; Ching-Shih Chen; Costas Koumenis; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2006-04-18       Impact factor: 4.436

2.  Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype.

Authors:  Bing Zhu; Li Zhang; Mikhail Alexeyev; Diego F Alvarez; Samuel J Strada; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-11-21       Impact factor: 5.464

3.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model.

Authors:  Keith L Black; Dali Yin; John M Ong; Jinwei Hu; Bindu M Konda; Xiao Wang; MinHee K Ko; Jennifer-Ann Bayan; Manuel R Sacapano; Andreas Espinoza; Dwain K Irvin; Yan Shu
Journal:  Brain Res       Date:  2008-07-14       Impact factor: 3.252

4.  Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response.

Authors:  Julie Hollien; Jonathan S Weissman
Journal:  Science       Date:  2006-07-07       Impact factor: 47.728

Review 5.  The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels.

Authors:  Bing Zhu; Samuel J Strada
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 6.  The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models.

Authors:  Andreas Friebe; Doris Koesling
Journal:  Nitric Oxide       Date:  2009-07-25       Impact factor: 4.427

7.  Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by down-regulation of NF-kappaB, ERK1/2, and p38 kinase.

Authors:  Chun Yeon Choi; Kyung-Ran Park; Jung-Hee Lee; Young Jin Jeon; Kwang-Hyeon Liu; Sangtaek Oh; Dong-Eun Kim; Sung Su Yea
Journal:  Eur J Pharmacol       Date:  2007-07-26       Impact factor: 4.432

8.  Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta.

Authors:  Anindita Das; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2008-08-21       Impact factor: 5.157

9.  OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.

Authors:  Margaret A Park; Adly Yacoub; Mohammed Rahmani; Guo Zhang; Lori Hart; Michael P Hagan; Stuart K Calderwood; Michael Y Sherman; Costas Koumenis; Sarah Spiegel; Ching-Shih Chen; Martin Graf; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2008-01-08       Impact factor: 4.436

10.  Regulated Ire1-dependent decay of messenger RNAs in mammalian cells.

Authors:  Julie Hollien; Jonathan H Lin; Han Li; Nicole Stevens; Peter Walter; Jonathan S Weissman
Journal:  J Cell Biol       Date:  2009-08-03       Impact factor: 10.539

View more
  29 in total

Review 1.  Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies.

Authors:  Kunyu Shen; David W Johnson; David A Vesey; Michael A McGuckin; Glenda C Gobe
Journal:  Cell Stress Chaperones       Date:  2017-09-27       Impact factor: 3.667

2.  HSPA5/Dna K may be a useful target for human disease therapies.

Authors:  Laurence Booth; Jane L Roberts; Paul Dent
Journal:  DNA Cell Biol       Date:  2015-03       Impact factor: 3.311

Review 3.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

4.  GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease.

Authors:  Laurence Booth; Jane L Roberts; Devin R Cash; Seyedmehrad Tavallai; Sophonie Jean; Abigail Fidanza; Tanya Cruz-Luna; Paul Siembiba; Kelly A Cycon; Cynthia N Cornelissen; Paul Dent
Journal:  J Cell Physiol       Date:  2015-07       Impact factor: 6.384

5.  Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.

Authors:  Yi-Hsien Chen; Lucy D'Agostino McGowan; Patrick J Cimino; Sonika Dahiya; Jeffrey R Leonard; Da Yong Lee; David H Gutmann
Journal:  Cell Rep       Date:  2015-03-12       Impact factor: 9.423

Review 6.  Beyond Alkylating Agents for Gliomas: Quo Vadimus?

Authors:  Vinay K Puduvalli; Rekha Chaudhary; Samuel G McClugage; James Markert
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

7.  AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication.

Authors:  Laurence Booth; Jane L Roberts; Heath Ecroyd; Sarah R Tritsch; Sina Bavari; St Patrick Reid; Stefan Proniuk; Alexander Zukiwski; Abraham Jacob; Claudia S Sepúlveda; Federico Giovannoni; Cybele C García; Elsa Damonte; Javier González-Gallego; María J Tuñón; Paul Dent
Journal:  J Cell Physiol       Date:  2016-06-06       Impact factor: 6.384

8.  Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.

Authors:  Timothy Webb; Jori Carter; Jane L Roberts; Andrew Poklepovic; William P McGuire; Laurence Booth; Paul Dent
Journal:  Cancer Biol Ther       Date:  2015-09-29       Impact factor: 4.742

Review 9.  How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.

Authors:  Mehdi Sanati; Samaneh Aminyavari; Hamid Mollazadeh; Bahram Bibak; Elmira Mohtashami; Amir R Afshari
Journal:  Pharmacol Rep       Date:  2022-01-20       Impact factor: 3.024

10.  OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies.

Authors:  Laurence Booth; Jane L Roberts; Mehrad Tavallai; Aida Nourbakhsh; John Chuckalovcak; Jori Carter; Andrew Poklepovic; Paul Dent
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.